Arch Therapeutics Stock Price, News & Analysis
ARTH
OTC
Company Description
Arch Therapeutics, Inc., a biotechnology company based in the United States, focuses on developing and marketing products utilizing its AC5 self-assembling technology platform. The company's products aim to stop bleeding, control leaking, and manage wounds during surgery, trauma, or from disease. Arch Therapeutics offers flagship products like the AC5 Advanced Wound System and AC5 Topical Hemostat for skin applications. Founded in 2006, the company is headquartered in Framingham, Massachusetts.
Stock Performance
$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$1.0M
Market Cap
4.4M
Shares outstanding
Latest News
SEC Filings
No SEC filings available for Arch Therapeutics.
Financial Highlights
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin
Upcoming Events
Frequently Asked Questions
What is the current stock price of Arch Therapeutics (ARTH)?
The current stock price of Arch Therapeutics (ARTH) is $0.1608 as of April 21, 2025.
What is the market cap of Arch Therapeutics (ARTH)?
The market cap of Arch Therapeutics (ARTH) is approximately 1.0M.
What does Arch Therapeutics, Inc. do?
Arch Therapeutics, Inc. operates as a biotechnology company that develops and markets products using its AC5 self-assembling technology platform for wound management.
Where is Arch Therapeutics, Inc. headquartered?
Arch Therapeutics, Inc. is based in Framingham, Massachusetts, in the United States.
When was Arch Therapeutics, Inc. founded?
Arch Therapeutics, Inc. was founded in 2006.
What are the flagship products of Arch Therapeutics, Inc.?
Arch Therapeutics offers products like the AC5 Advanced Wound System and AC5 Topical Hemostat for skin applications.
What is the focus of products developed by Arch Therapeutics, Inc.?
The products developed by Arch Therapeutics aim to stop bleeding, control leaking, and manage wounds during surgery, trauma, or from disease.
What is the contact information for Arch Therapeutics, Inc. Investor Relations?
For Investor Relations, contact Arch Therapeutics at +1-855-340-ARTH (2784) for US and Canada, or email at investors@archtherapeutics.com.
Who is the Chief Financial Officer of Arch Therapeutics, Inc.?
The Chief Financial Officer of Arch Therapeutics, Inc. is Michael Abrams. Contact him at 617-680-7841 or email at mabrams@archtherapeutics.com.
What are the investigational devices offered by Arch Therapeutics, Inc.?
AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use by Arch Therapeutics, Inc.
What are the trademarks associated with Arch Therapeutics, Inc.?
AC5, AC5-G, AC5-V, and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.
What is a significant milestone planned by Arch Therapeutics, Inc.?
A common stock listing on a national exchange is the next planned significant milestone for Arch Therapeutics, Inc.